Brachytherapy

Papers
(The TQCC of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
BP02 Presentation Time: 4:09 PM33
PPP03 Presentation Time: 10:48 AM33
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM22
PHSOR06 Presentation Time: 9:25 AM19
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM19
PO024918
PO032415
MPP02 Presentation Time: 4:09 PM14
BP08 Presentation Time: 5:03 PM14
PO042514
PPP02 Presentation Time: 10:39 AM14
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer13
PO022713
PO041713
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data12
GPP03  Presentation Time: 9:33 AM11
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study11
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications11
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost10
PO3510
P010510
Editorial Board10
PHSOP2  Presentation Time: 9:05 AM10
Editorial Board9
PSOR8  Presentation Time: 12:05 PM9
PO939
PSOR03  Presentation Time: 12:10 PM9
PO479
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po9
PSOR12  Presentation Time: 5:25 PM9
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy8
PL02 Presentation Time: 1:45 PM8
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy8
MSOR11 Presentation Time: 8:50 AM8
PO02348
PO04218
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes8
Author Index7
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma7
PPP04  Presentation Time: 10:57 AM7
PSOR02  Presentation Time: 4:35 PM7
PRPP05  Presentation Time: 11:06 AM7
Determination of the optimal time for planning SAVI brachytherapy for APBI7
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement7
PL02  Presentation Time: 1:45 PM7
P03017
MSOR12 Presentation Time: 8:55 AM7
PP05  Presentation Time: 5:06 PM7
Masthead7
Table of Contents6
GSOR14  Presentation Time: 11:35 AM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM6
PO216
PO106
PP02  Presentation Time: 9:10 AM6
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
PO206
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy6
The case for risk-stratified IORT for early breast cancer6
High-dose-rate brachytherapy for airway malignancy a single institution experience6
PO46  Presentation Time: 4:45 PM6
Masthead6
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy5
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts5
PHSOR04  Presentation Time: 12:45 PM5
GSOR04  Presentation Time: 12:15 PM5
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
PO02415
PO02425
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life5
PHSOR05  Presentation Time: 12:50 PM5
Partial breast irradiation: An updated consensus statement from the American brachytherapy society5
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
PSOR02 Presentation Time: 11:35 AM5
Skin Posters PO07015
PO01195
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
MSPP03  Presentation Time: 4:20 PM5
Table of Contents5
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy5
PO04245
PO01095
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal4
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer4
MSOP03  Presentation Time: 8:10 AM4
GSOR13  Presentation Time: 12:30 PM4
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
PP02  Presentation Time: 10:09 AM4
PO1144
Development of a dosimetric phantom using OSLDs or TLD-100 for external audits of high-dose-rate 192Ir brachytherapy sources: Preliminary results4
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
MSOP06  Presentation Time: 8:25 AM4
GPP06  Presentation Time: 11:15 AM4
PO154
PO194
PO914
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing4
MPP02  Presentation Time: 4:09 PM4
PHSOR06  Presentation Time: 12:55 PM4
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation4
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
PSOR7  Presentation Time: 12:00 PM3
PRPP02  Presentation Time: 10:39 AM3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Comment on “high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement”3
MSOR11 Presentation Time: 5:50 PM3
PO02613
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy3
PO863
PO33  Presentation Time: 10:30 AM3
PP05  Presentation Time: 11:36 AM3
PSOR3  Presentation Time: 11:40 AM3
GPP04  Presentation Time: 9:42 AM3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
PRSOP08  Presentation Time: 12:05 PM3
A primer on time-driven activity-based costing in brachytherapy3
GSOR09 Presentation Time: 12:10 PM3
PRSOP03  Presentation Time: 11:40 AM3
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PO523
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
PPP05 Presentation Time: 11:06 AM3
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
P03043
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
PO02203
PO03203
PO01103
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
PO40  Presentation Time: 4:45 PM3
PO533
PO27  Presentation Time: 7:40 AM2
PO01112
PHSOR08  Presentation Time: 1:05 PM2
GSOR06 Presentation Time: 5:25 PM2
MPP05  Presentation Time: 4:36 PM2
PO03102
PO02292
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
Table of Contents2
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
Table of Contents2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
MSOR7 Presentation Time: 5:30 PM2
PO03112
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
PP04  Presentation Time: 11:27 AM2
PP02  Presentation Time: 8:29 AM2
Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center2
PHSOP6  Presentation Time: 9:25 AM2
GSOR02  Presentation Time: 11:35 AM2
MSS11  Presentation Time: 4:35 PM2
P01142
PL03 Presentation Time: 2:00 PM2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PO02332
Masthead2
PO04282
GYN Posters PO012
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system2
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
Masthead2
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
PO04082
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
MSOR9 Presentation Time: 5:40 PM2
PO02582
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms2
PSA: Declining utilization of prostate brachytherapy2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
GSOR06  Presentation Time: 11:55 AM2
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Systematic review of brachytherapy for symptom palliation2
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
Table of Contents2
PO03142
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
MSPP05  Presentation Time: 4:40 PM2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
PO102
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
GSOR10 Presentation Time: 12:15 PM2
GSOR12 Presentation Time: 5:55 PM2
Development of a phantom and analysis of brachytherapy dosimetry using the sulfamic acid/electron paramagnetic resonance system2
Actinium-225 Targeted Agents: Where Are We Now?2
PP04  Presentation Time: 9:47 AM2
PO322
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
PO122
PO492
PPP03  Presentation Time: 10:48 AM2
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
GSOR10 Presentation Time: 5:45 PM1
PP04 Presentation Time: 4:27 PM1
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
Local seed displacement from Day 0 to Day 30 in I-125 permanent prostate brachytherapy: A detailed, computed tomography-based analysis1
P01061
PO28  Presentation Time: 7:40 AM1
P01111
PO1001
BP04 Presentation Time: 4:27 PM1
Brachytherapy outcome modeling in cervical cancer patients: A predictive machine learning study on patient-specific clinical, physical and dosimetric parameters1
PO03091
PO02111
PO02021
PO04331
Saturday, July 13, 20249:00 AM - 10:00 AMPHSOR01 Presentation Time: 9:00 AM1
MSOR10 Presentation Time: 8:45 AM1
Inter-observer effects in needle reconstruction for temporary prostate brachytherapy: Dosimetric implications and adaptive CBCT-TRUS registration solutions1
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
PO171
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer1
PO01021
Sunday, June 19, 2022 10:30 AM - 11:30 AMPP07  Presentation Time: 10:30 AM1
Masthead1
PO1191
PPP06 Presentation Time: 11:15 AM1
GSOR03  Presentation Time: 11:40 AM1
MSS04  Presentation Time: 4:00 PM1
PO02031
PO01161
PSOR12 Presentation Time: 12:25 PM1
GSOR08 Presentation Time: 5:35 PM1
PPP01  Presentation Time: 4:00 PM1
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
GPP02  Presentation Time: 9:24 AM1
PO131
PO02401
Re: Letter to the editor with regards to “Impact of detector selection on commissioning of Leipzig surface applicators with improving immobilization in high-dose-rate brachytherapy” by Li et al.1
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
PO02631
0.16122007369995